Background: Evidence suggests that inter-patient variability in anthracycline metabolic rate
drugs, which is largely a reflection of differences in the phase I conversion of anthracyclines to their metabolites catalyzed by the AKRs and CBRs (1) . A cardioprotective role for CBRs has been demonstrated in mouse models (2, 3) and it has been proposed that polymorphisms in these genes are likely to affect anthracycline metabolic rates and thus contribute to AIC. We have previously shown that 13 of the naturally occurring nsSNPs in the reductase genes have a significant effect on the metabolism of anthracyclines in vitro (4). Here we evaluate these nsSNPs for their association with AIC in a population of AML patients undergoing DAUNbased chemotherapy. Initially, a base model for predicting LVEF % drop was built from the non-genetic variables (ie. gender, age, and cumulative dose) using stepwise addition based on Akaike's Information Criterion. Only the non-genetic variables predictive of the outcome were included in the genetic model.
Material and Methods

Peripheral
The joint effect of all SNPs on LVEF % drop was assessed using a global test of association and the individual effects of each SNP were assessed with standard likelihood ratio tests (5). All analyses were adjusted for gender and cumulative dose after applying a logarithmic transformation to stabilize the outcome variance.
All statistical analyses were performed within the R software environment for statistical computing, using the GlobalTest package (6) .
Results
Of the 13 nsSNPs included in the study 5 passed the QC filters and were used in statistical analysis (bolded SNPs in Table 1 ). Initial tests for association of non-genetic variables with percent drop in LVEF identified only cumulative dose and gender to be predictive of LVEF drop. Therefore, all tests for the effect of the SNPs on the outcome were adjusted for cumulative dose and gender. The likelihood ratio tests for association of each SNP individually found no association for any of the 5 SNPs with LVEF drop (Table 2) . Furthermore, no association was found when all 5 SNPs were tested for joint effect (p=0.889). Given that cumulative dose could potentially be a modifying variable we also tested the effect of the SNPs individually and jointly including linear interaction terms with dose. These tests similarly did not detect any significant associations ( 
Discussion
The aim of this study was to determine if any of the nsSNPs in reductase genes with a demonstrated in vitro effect on anthracycline metabolism are associated with AIC in a population of AML patients. Since serial measurements of LVEF are commonly used to monitor asymptomatic cardiotoxicity during anthracycline chemotherapy (1), we used the percent drop in LVEF as a measure of acute cardiotoxicity. We found no association between the nsSNPs in reductase genes and AIC in either individual or joint effects models.
To the best of our knowledge of the SNPs investigated here only rs1056892 (V244M) in CBR3 has been previously tested for association with AIC, and was found to be associated in survivors of childhood cancers by Blanco et al. but not by Visscher et al. (7, 8) . Similar, to Visscher et al. we did not find an association between the SNP and AIC in a population of adult AML patients. However, our study differs from previous studies in that it is looking at acute and not chronic cardiotoxicity in adult population.
In summary, despite their demonstrated in vitro effect on anthracycline metabolism, the nsSNPs in reductase genes were not associated with DAUN induced cardiotoxicity. However, given that AIC is a complex phenotype it is possible that these variants may improve predictive power of polygenic models in the future.
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